Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Stock
Key stats
- Market cap
- $4.05B
- Price / Earnings ratio
- 140.5x
- EPS (TTM)
- -$15.83
- Volume
- Loading
- 52-week high
- $33.30
- 52-week low
- $19.30
Source: third-party data provider, as of October 24, 2026
Compare with ARQT
Recent news

2 Stocks That Could Soar in Q4
2 Stocks That Could Soar in Q4
ARQT

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
ARQT

Here's Why You Should Add ARQT Stock to Your Portfolio Now
Here's Why You Should Add ARQT Stock to Your Portfolio Now
ARQT

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
ARQT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 70.34
- MACD 12/26/9
- 1.65
- EMA 9 of MACD
- 0.92
- MACD histogram
- 0.73
- SMA 50
- $25.98
- Price above SMA 50
- EMA 50
- $26.76
- Price above EMA 50
- SMA 200
- $25.13
- Price above SMA 200
- EMA 200
- $25.77
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

2 Stocks That Could Soar in Q4
2 Stocks That Could Soar in Q4
ARQT

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
ARQT

Here's Why You Should Add ARQT Stock to Your Portfolio Now
Here's Why You Should Add ARQT Stock to Your Portfolio Now
ARQT

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
ARQT

5 Biotech Stocks Worth Adding to Your Portfolio Now
5 Biotech Stocks Worth Adding to Your Portfolio Now
ARQT

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
ARQT

Arcutis Biotherapeutics Q2 Earnings Call Highlights
Arcutis Biotherapeutics Q2 Earnings Call Highlights
ARQT

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
ARQT

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ARQT

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet
ARQT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Arcutis Biotherapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Todd Franklin Watanabe M.A. | President, CEO & Director | 1968 |
| Ms. Latha Vairavan | Senior VP & Chief Financial Officer | 1978 |
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder & Director Emeritus | 1955 |
| Mr. Masaru Matsuda Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary | 1971 |
| Dr. Patrick E. Burnett M.D., Ph.D. | Executive VP & Chief Medical Officer | 1972 |
| Mr. Brian Schoelkopf | Head of Investor Relations | — |
| Mr. Steve Arias | Vice President of Compliance & Privacy | — |
| Ms. Amanda Sheldon | Head of Corporate Communications | — |
| Ms. Aleen Hosdaghian | Vice President of Marketing | — |
| Mr. Todd Tucker | Senior VP & Chief Human Resources Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 70.34
- MACD 12/26/9
- 1.65
- EMA 9 of MACD
- 0.92
- MACD histogram
- 0.73
- SMA 50
- $25.98
- Price above SMA 50
- EMA 50
- $26.76
- Price above EMA 50
- SMA 200
- $25.13
- Price above SMA 200
- EMA 200
- $25.77
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $38.00
- Average
- $42.50
- High
- $48.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.2 | -27.5 | +34.2 | |||||||||
| 2022 | -33.7 | +14.8 | +10.1 | -0.7 | -2.2 | +5.0 | +11.6 | +33.0 | -28.9 | -7.9 | -5.4 | -13.3 |
| 2023 | +12.2 | -3.9 | -34.1 | +24.1 | -47.8 | +24.6 | +24.7 | -19.2 | -40.7 | -52.3 | -18.6 | +62.3 |
| 2024 | +71.1 | +54.8 | -15.8 | -14.0 | -5.4 | +13.8 | +5.3 | +14.8 | -11.4 | -13.0 | +50.4 | +12.2 |
| 2025 | -9.1 | +7.9 | +21.9 | -0.5 | -11.0 | +4.0 | +6.0 | +8.6 | +23.0 | +28.1 | +23.8 | -4.4 |
| 2026 | -12.5 | +5.5 | -4.8 | -3.7 | -8.1 | +22.1 | +3.9 | -7.6 | +11.3 | +27.3 |



